Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant…


Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces today that the last patient has been enrolled in its 22-site U.S. Phase II trial for its BK polyomavirus (“BKV”)-neutralizing antibody, potravitug.

Read more from the original source:
Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant...

Related Posts